OCT 19, 2026 · JOURNAL ARTICLE
Retrospective analysis of real-world elacestrant use in two large Austrian cancer centers
Breast Care
Background: Elacestrant is an oral selective estrogen receptor degrader (SERD) approved for the treatment of hormone receptor–positive (HR-positive), human epidermal growth factor